Therefore, we hypothesized that IPO5 may interact with the NLS of RASAL2, resulting in RASAL2 nuclear translocation and eliminating the inhibitory effect of RASAL2 in the cytoplasm; this would subsequently augment the RAS pathway and would ultimately drive CRC progression. Here, IPO5 is linked to colorectal carcinoma.